Business Context and Reporting Period
This Form 8-K is a current report filed by Biozone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc.) on March 30, 2011, regarding events occurring on March 29, 2011. The filing discloses the issuance of unregistered securities to fund a planned acquisition.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company issued and sold secured convertible promissory notes with an aggregate principal amount of $2,250,000.
- Interest Rate: Notes bear interest at 10% per annum.
- Maturity Date: September 29, 2011, or the closing date of the Target Transaction Financing, whichever is earlier.
- Liquidity Impact: Proceeds are intended to fund a "Target Transaction" (acquisition of one or more businesses) and related financing.
- Equity Component: Warrants were issued alongside the notes, exercisable for five years at 120% of the price of securities sold in the Target Transaction Financing.
Material Changes and Terms
The filing details a significant change in the Company's capital structure through a private placement to accredited investors under Section 4(2) and Rule 506 exemptions. Key terms include:
- Conversion Rights: Upon consummation of the Target Transaction Financing, holders may convert principal and accrued interest into securities at 80% of the offering price or demand cash repayment.
- Penalty Fees: If the notes are not prepaid or converted by the maturity date, a penalty fee is triggered (calculated as a pro-rata share of $100,000 based on the $2,000,000 threshold).
- Default/Extension Penalty: If the Target Transaction has not closed by September 29, 2011, the Company must pay 150% of the outstanding principal plus accrued interest.
- Warrant Coverage: Ranges from 50% to 100% of the principal amount depending on the timing of the Target Transaction closing (within 120, 150, or after 150 days).
Outlook, Risks, and Contingencies
The Company intends to consummate a Target Transaction within 120 days of the private placement closing. The financial obligations are contingent on this transaction:
- Contingency Risk: Failure to close the Target Transaction by the maturity date triggers a severe financial penalty (150% repayment).
- Dilution Risk: Warrants include a "ratchet" anti-dilution adjustment for one year, reducing the exercise price if the Company issues securities at a lower price.
- Management Commentary: The filing states the Company will use its "best efforts" to obtain financing for the Target Transaction but does not guarantee success.
Investor Verification Checklist
- Verify the identity of the "Target Transaction" and the specific businesses intended for acquisition.
- Confirm the Company's current cash position and ability to service the 10% interest or repay the 150% penalty if the acquisition fails.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for additional covenants or restrictions.
- Assess the potential dilution impact of the warrants, particularly given the ratchet provision.
- Note the discrepancy between the request metadata (Cocrystal Pharma) and the filing registrant (Biozone Pharmaceuticals).